Table 5.
Comparison of the percentages of γδ T cell subsets in IFN-β-treated MS patients stratified to the NEDA or EDA groups
| MS w/IFN-β | HCs (n = 44) | p value (K-W test) | padj value | ||||
|---|---|---|---|---|---|---|---|
| NEDA (n = 8) | EDA (n = 13) | NEDA vs. HCs | EDA vs. HCs | NEDA vs. EDA | |||
| Vδ1+ | 39.5 (21.1–55.9) | 17.4 (11.6–38.5) | 18.4 (11.6–34.2) | NS | – | – | – |
| Vδ1+Vγ9+ | 3.01 (1.32–10.7) | 2.99 (1.60–3.94) | 2.15 (1.12–4.71) | NS | – | – | – |
| Vδ1+Vγ9– | 36.4 (17.5–51.9) | 15.2 (9.18–31.9) | 15.5 (8.47–31.5) | NS | – | – | – |
| Vδ2+ | 14.2 (3.17–25.2) | 24.7 (6.33–42.9) | 54.9 (31.7–65.9) | < 0.001 | < 0.001 | 0.006 | NS |
| Vδ2+Vγ9+ | 14.1 (2.76–25.0) | 24.3 (6.09–42.8) | 54.3 (31.1–65.7) | < 0.001 | < 0.001 | 0.005 | NS |
| Vδ2+Vγ9– | 0.12 (0.00–0.26) | 0.18 (0.06–0.84) | 0.08 (0.03–0.29) | NS | – | – | – |
| Vδ1−Vδ2− | 32.3 (20.0–61.8) | 36.1 (28.4–54.0) | 22.8 (17.1–30.3) | < 0.001 | 0.033 | < 0.001 | NS |
| Vδ1−Vδ2−Vγ9+ | 1.68 (0.30–2.83) | 1.01 (0.26–2.23) | 2.42 (1.25–3.83) | 0.025 | NS (0.061) | 0.022 | NS |
| Vδ1−Vδ2−Vγ9– | 28.2 (17.1–60.7) | 35.1 (27.5–51.0) | 18.1 (10.7–26.4) | < 0.001 | 0.011 | < 0.001 | NS |
Values are the median (IQR). Percentages of each population in total γδ T cells are shown
p values (K-W test) were obtained by Kruskal-Wallis analyses, and if they were statistically significant, then padj values were calculated using multivariate linear regression analyses adjusted for age and sex
EDA evidence of disease activity, HCs healthy controls, IFN-β interferon-β, IQR interquartile ranges, K-W Kruskal-Wallis, MS multiple sclerosis, NEDA no-evidence of disease activity, NS not significant, w/ with